← Leaderboards
Richard B Bankert
Roswell Park Cancer Institute Corp
$9,763,302
Attributed
$9,763,302
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$9,763,302 · 8
By mechanism
R01$9,073,874 · 6
R56$396,250 · 1
R43$293,178 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Pawel Kalinski$15,491,276
- Walter J Storkus$19,974,413
- Sharon S Evans$8,115,501
- Scott I. Abrams$11,133,748
- Renier Joseph Brentjens$12,958,252
Others in their field
Top investigators on “Cytokine”
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$83,965,880
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Fulton T Crews · University Of North Carolina Chapel Hill$36,249,590
- Marianne Ward · Duke University$34,872,957
- Joren C Madsen · Massachusetts General Hospital$33,058,731
- Barton F Haynes · Duke University$29,068,807
Research focus
CytokineT-LymphocyteCellsDesignXenograft ModelT-Cell ReceptorMonitorNeoplastic CellDendritic CellsT Memory CellTumorSignal TransductionCd8b1 GeneKillingsPreventMolecularIn VivoResponseLung NeoplasmsReceptor SignalingT-Cell ActivationOvarian NeoplasmCancer PatientTumor Progression
Grant awards (35)
Novel Drug for Cancer Immunotherapy that Targets Phosphatidylserine$293,178
R43 · FY2021 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$326,466
R01 · FY2017 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$326,400
R01 · FY2016 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$326,334
R01 · FY2015 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$319,024
R01 · FY2014 · CA · contact PI
CD4+ Memory T-Cells in Human Tumor Microenvironment$287,818
R01 · FY2014 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$353,042
R01 · FY2013 · CA · contact PI
CD4+ Memory T-Cells in Human Tumor Microenvironment$278,916
R01 · FY2013 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$335,374
R01 · FY2012 · CA · contact PI
CD4+ Memory T-Cells in Human Tumor Microenvironment$296,719
R01 · FY2012 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$335,421
R01 · FY2011 · CA · contact PI
CD4+ Memory T-Cells in Human Tumor Microenvironment$296,719
R01 · FY2011 · CA · contact PI
Role of Memory T Cells in Pathogenesis and Resolution of Inflammatory Diseases$396,250
R56 · FY2010 · AI · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$345,843
R01 · FY2010 · CA · contact PI
CD4+ Memory T-Cells in Human Tumor Microenvironment$323,034
R01 · FY2010 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$345,888
R01 · FY2009 · CA · contact PI
CD4+ Memory T-Cells in Human Lung Tumor Micorenvironment$290,964
R01 · FY2009 · CA · contact PI
Re-activating Memory T Cells in the Microenvironment of Human Tumors$370,088
R01 · FY2008 · CA · contact PI
CD4+ Memory T-Cells in Human Lung Tumor Micorenvironment$290,964
R01 · FY2008 · CA · contact PI
CD4+ Memory T-Cells in Human Lung Tumor Micorenvironment$290,964
R01 · FY2007 · CA · contact PI
CD4+ Memory T-Cells in Human Lung Tumor Micorenvironment$299,654
R01 · FY2006 · CA · contact PI
CD4+ Memory T-Cells in Human Lung Tumor Micorenvironment$306,865
R01 · FY2005 · CA
VH IG PEPTIDE VACCINES FOR HUMAN B CELL MALIGNANCIES$372,345
R01 · FY2003 · CA
VH Peptide Vaccine Strategies for B Cell Lymphomas$235,500
R01 · FY2003 · CA
VH IG PEPTIDE VACCINES FOR HUMAN B CELL MALIGNANCIES$359,210
R01 · FY2002 · CA
VH Peptide Vaccine Strategies for B Cell Lymphomas$234,250
R01 · FY2002 · CA
VH IG PEPTIDE VACCINES FOR HUMAN B CELL MALIGNANCIES$321,279
R01 · FY2001 · CA
VH Peptide Vaccine Strategies for B Cell Lymphomas$232,750
R01 · FY2001 · CA
IMMUNITY AND IMMUNOTHERAPY OF HUMAN CANCER IN SCID MICE$119,005
R01 · FY2001 · CA
VH IG PEPTIDE VACCINES FOR HUMAN B CELL MALIGNANCIES$54,061
R01 · FY2001 · CA
IMMUNITY AND IMMUNOTHERAPY OF HUMAN CANCER IN SCID MICE$21,419
R01 · FY2001 · CA
VH IG PEPTIDE VACCINES FOR HUMAN B CELL MALIGNANCIES$342,724
R01 · FY2000 · CA
FACTORS AFFECTING LUNG TUMOR GROWTH IN SCID MICE$282,872
R01 · FY2000 · CA
IMMUNITY AND IMMUNOTHERAPY OF HUMAN CANCER IN SCID MICE$136,336
R01 · FY2000 · CA
FACTORS AFFECTING LUNG TUMOR GROWTH IN SCID MICE$15,626
R01 · FY2000 · CA